JA­MA study finds can­cer drug da­ta is still large­ly un­avail­able to qual­i­fied re­searchers

As da­ta shar­ing has be­come more help­ful and rel­e­vant to re­searchers in the past few years, a new re­port in JA­MA On­col­o­gy shows that the avail­abil­i­ty of can­cer drugs’ clin­i­cal tri­al da­ta is still lag­ging for re­searchers.

An au­dit from Aus­tralian re­searchers found that less than half of in­di­vid­ual par­tic­i­pants’ da­ta from tri­als is shared with re­searchers.

The re­port, which was pub­lished on Thurs­day, not­ed that de­ci­sions by reg­u­la­tors and clin­i­cians on whether to ap­prove and use new med­ica­tions are typ­i­cal­ly based on find­ings from piv­otal clin­i­cal tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER